156 related articles for article (PubMed ID: 21703972)
21. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
23. Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis.
Wang Z; Zhang Y; Du Y; Song F; Gao S
Hematology; 2021 Dec; 26(1):144-152. PubMed ID: 33491603
[TBL] [Abstract][Full Text] [Related]
24. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
[TBL] [Abstract][Full Text] [Related]
25. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
26. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
27. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
29. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
30. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
[TBL] [Abstract][Full Text] [Related]
31. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
32. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Pérez-García A; Brunet S; Berlanga JJ; Tormo M; Nomdedeu J; Guardia R; Ribera JM; Heras I; Llorente A; Hoyos M; Esteve J; Besalduch J; Bueno J; Sierra J; Gallardo D;
Leukemia; 2009 Mar; 23(3):486-91. PubMed ID: 19092854
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
[TBL] [Abstract][Full Text] [Related]
34. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
35. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.
Sobecks RM; Askar M; Thomas D; Rybicki L; Kalaycio M; Dean R; Avery R; Mossad S; Copelan E; Bolwell BJ
Exp Clin Transplant; 2011 Feb; 9(1):7-13. PubMed ID: 21605017
[TBL] [Abstract][Full Text] [Related]
37. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
[TBL] [Abstract][Full Text] [Related]
38. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation].
Zhou Z; Wang M; He Y
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036
[TBL] [Abstract][Full Text] [Related]
39. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
[TBL] [Abstract][Full Text] [Related]
40. CTLA-4 polymorphism rs231775: Influence on relapse and survival after allogeneic hematopoietic stem cell transplantation in childhood.
Hammrich J; Wittig S; Ernst T; Gruhn B
Eur J Haematol; 2019 Mar; 102(3):251-255. PubMed ID: 30465728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
